Patent Grant
10421824
The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 19, 2014, is named A-1808-US-NP_SL.txt and is 95,780 bytes in size.
The bispecific molecules described herein are within the field of protein therapeutics.
Most therapeutic proteins bind to a single target protein with high specificity, thereby interfering with the activity of this single target protein. That protein may be a part of one or more biological pathways that mediate a human disease being treated, and the therapeutic protein may therefore inhibit disease progression. However, efficacy of therapeutic proteins is rarely complete for all patients. Incomplete efficacy of therapeutic proteins could be due in some cases to the complexity of a disease. For example, some diseases may be mediated by multiple biological pathways, or different biological pathways may play a predominant role in mediating disease activity in different patients having the same clinically-defined condition. Hence, in some diseases it may be advantageous to simultaneously inhibit at least two biological pathways.
Herein is provided a bispecific protein that can bind to and inhibit the biological activity of both B7RP1 and BAFF. BAFF plays a role in B cell survival, and B7RP1 plays a role in T cell costimulation. Thus, a protein that inhibits the activity of both proteins interferes with the activity of both B and T cells.
Described herein is bispecific protein, wherein the protein can inhibit BAFF-mediated proliferation of human B cells and wherein the protein can inhibit B7RP1-mediated proliferation of human T cells. The bispecific protein can comprise an IgG antibody comprising two immunoglobulin heavy chains having different amino acid sequences and two immunoglobulin light chains having different amino acid sequences. The IgG antibody can inhibit BAFF-mediated proliferation of human B cells and B7RP1-mediated proliferation of human T cells The IgG antibody can be an IgG1, IgG2, IgG3, or IgG4 antibody and can be a human or humanized IgG antibody. The bispecific protein can comprise a light chain complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO:8, a light chain complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO:9, a light chain complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO:10, a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:11, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:12, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:13. Further, the bispecific protein can comprise a heavy chain variable region comprising SEQ ID NO:15 or a variant thereof and a light chain variable region comprising SEQ ID NO:14 or a variant thereof. Such variant sequences can comprise not more than 10 deletions, insertions of substitutions of a single amino acid per 100 amino acids relative to a reference sequence.
In an alternate embodiment, a bispecific protein that can inhibit BAFF-mediated proliferation of human B cells and that can inhibit B7RP1-mediated proliferation of human T cells can comprise: (a) a polypeptide comprising an amino acid sequence having the following formula: A-L1-P-L2-P, wherein A is an immunoglobulin heavy chain of an IgG antibody, L1 is a first linker of that is absent or is 3 to 40 amino acids long, P is a BAFF-binding peptide that is 10 to 40 amino acids long, and L2 is a peptide linker that is absent or is 5 to 50 amino acids long; and (b) an immunoglobulin light chain. The immunoglobulin heavy chain of (a) and the immunoglobulin light chain of (b) can form an IgG antibody that can bind B7RP1 and/or can inhibit B7RP1-mediated proliferation of human T cells. The immunoglobulin heavy chain may be missing a lysine at its C-terminal end just upstream of L1. The IgG antibody can be a human or humanized IgG1, IgG2, IgG3, or IgG4 antibody. The BAFF-binding peptide P can have the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. L1 can have the amino acid sequence of SEQ ID NO:4, 43, 45, or 46. L2 can have the amino acid sequence of SEQ ID NO:5, 6, or 7. The bispecific protein can comprise a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:8 (RASQGISNWLA), a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:9 (AASSLQS), a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:10 (QQYDSYPRT), a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:11 (SYWMS), a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:12 (YIKQDGNEKYYVDSVKG), and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:13 (EGILWFGDLPTF). The bispecific protein can comprise an immunoglobulin light chain variable region comprising the amino acid sequence of SEQ ID NO:14 and/or an immunoglobulin heavy chain variable region comprising the amino acid sequence of SEQ ID NO:15. The bispecific protein can comprise the amino acid sequence of SEQ ID NO:19 or a variant thereof and the amino acid sequence of SEQ ID NO:17 or 18 or variants thereof. Such variant sequences can comprise not more than 10 deletions, insertions of substitutions of a single amino acid per 100 amino acids relative to the reference sequence.
In a further aspect, herein is described a bispecific protein comprising: (a) a polypeptide comprising the amino acid sequence of SEQ ID NO:17 or SEQ ID NO:18 or variants thereof; and (b) another polypeptide comprising the amino acid sequence of SEQ ID NO:19 or a variant thereof. Such variant sequences can comprise not more than 10 deletions, insertions of substitutions of a single amino acid per 100 amino acids relative to the reference sequence. The bispecific protein can inhibit BAFF-mediated proliferation of human B cells and B7RP1-mediated proliferation of human T cells. The bispecific protein can be a tetramer comprising two molecules of the polypeptide of (a) and two molecules of the polypeptide of (b).
In another embodiment, herein is provided a protein comprising a linker comprising the amino acid sequence of SEQ DI NO:6 or SEQ ID NO:7.
Further, herein is described a pharmaceutical composition comprising any of the bispecific proteins herein described or the protein comprising the amino acid sequence of SEQ ID NO:6 or 7 and a physiologically acceptable excipient.
Also described herein is a nucleic acid encoding any polypeptide included in one of bispecific proteins herein described. Exemplary nucleic acids encoding a polypeptide included in a bispecific protein include, for example, SEQ ID NOs: 60, 61, 62, and 63, among others. Vectors comprising such nucleic acids and host cells containing such vectors and/or nucleic acids are described. Further described herein is method for making a bispecific protein comprising culturing the host cell containing a nucleic acid encoding any of the bispecific proteins described herein under conditions such that the nucleic acid is expressed and recovering the protein from the cell mass or the culture medium. The host cell can be a mammalian cell, for example, a CHO cell, or a bacterial cell such as Eschericha coli.
In another aspect, described herein is a method for treating systemic lupus erythematosus comprising administering to a patient a therapeutically effective amount of any of the bispecific proteins described herein or a pharmaceutical composition comprising such a bispecific protein. Another therapeutic can be administered to the patient before, after, or concurrently with the bispecific protein. The other therapeutic can be a corticosteroid, an antimalarial, retinoic acid, an NSAID, cyclophosphamide, dehydroepiandrosterone, mycophenolate mofetil, azathioprine, chlorambucil, methotrexate, tacrolimus, dapsone, thalidomide, leflunomide, or cyclosporine.
In a further aspect, herein is described a method of treatment comprising administering to a patient a therapeutically effective amount of any of the bispecific proteins described herein or a pharmaceutical composition comprising a bispecific protein described herein, wherein the patient has a disease selected from the group consisting of: ANCA-positive vasculitis, rheumatoid arthritis (RA), Crohn's disease, ulcerative colitis, celiac disease, pemphigus, pemphigoid, subacute cutaneous lupus erythematosus (SCLE), multiple sclerosis, chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, Goodpasture's syndrome, glomerulonephritis, autoimmune hemolytic anemia (AIHA), idiopathic thrombocytopenic purpura (ITP), chronic active hepatitis, primary billiary cirrhosis, Sjogren's syndrome, systemic sclerosis, Hashimoto's thyroiditis, Graves' disease, Addison's disease, and multiple endocrine neoplasia (MEN).
In another aspect, herein is described a pharmaceutical composition comprising any of the bispecific protein herein described. The pharmaceutical composition can be for the treatment of systemic lupus erythematosus or lupus nephritis.
In another aspect, the use of any of the bispecific proteins provided herein as a medicament is described.
Provided herein are bispecific proteins that bind to and inhibit both B cell activating factor (BAFF; also known as BLYS, TALL1, THANK, or TNFSF13B) and B7-related protein 1 (B7RP1; also known as ICOS Ligand, ICOSL, LICOS, B7 Homolog 2, B7H2, and GL50), nucleic acids encoding these bispecific proteins, and methods of making and using these proteins. The bispecific proteins can inhibit both BAFF-mediated B proliferation and B7RP1-mediated T cell proliferation. In another aspect, the bispecific proteins can inhibit B7RP1 binding to T cells. Such a bispecific protein can be an IgG antibody comprising two different immunoglobulin heavy chains and two different immunoglobulin light chains, where one heavy chain/light chain pair binds to BAFF and the other binds to B7RP1. Alternatively, the B7RP1-binding portion of the bispecific protein can comprise an IgG antibody including two identical heavy chains and two identical light chains, and the BAFF-binding portion of the bispecific protein can comprise one or more BAFF-binding peptides, which can be fused to the anti-B7RP1 antibody, optionally via the N-terminus of the immunoglobulin heavy or light chain, the carboxyterminus of the immunoglobulin heavy chain, and/or within the CH2 and/or CH3 region of the immunoglobulin heavy chain.
An “antibody,” as meant herein, is a protein comprising a heavy and/or light chain immunoglobulin variable region.
A “bispecific” protein, as meant herein is a protein that can bind specifically to two different molecules, which, in some embodiments, are proteins. For example, in some embodiments, a bispecific protein can bind to both BAFF and B7RP1.
A patient is receiving “concurrent” treatment with two or more therapeutics when the patient receives the two or more therapeutics during the same general timeframe, optionally at the very same time. For example, if a patient were dosed with one therapeutic daily on an ongoing basis and were also dosed with another therapeutic once a month on an ongoing basis, the patient would be receiving these two drugs concurrently. Similarly, a patient dosed with two different therapeutics, each administered every two weeks, but not on the same day, would be receiving concurrent treatment with the two therapeutics. Further, a patient receiving one therapeutic on an ongoing basis once per week and another therapeutic once per day for only three days would be receiving treatment for a short period of time with these two therapeutics.
As meant herein, an “Fc region” is a dimer consisting of two polypeptide chains joined by one or more disulfide bonds, each chain comprising part or all of a hinge domain plus a CH2 and a CH3 domain. Each of the polypeptide chains is referred to as an “Fc polypeptide chain.” More specifically, the Fc regions contemplated for use with the present invention are IgG Fc regions, which can be mammalian, for example human, IgG1, IgG2, IgG3, or IgG4 Fc regions. Among human IgG1 Fc regions, at least two allelic types are known. The amino acid sequences an Fc polypeptide chain can vary from those of a mammalian Fc polypeptide by no more than 20, 15, 12, 10, 8, 5, or 3 substitutions, insertions, or deletions of a single amino acid relative to a mammalian Fc polypeptide amino acid sequence. Alternatively or in addition, the amino acid sequence of an Fc polypeptide chain can vary from the sequence of a known or naturally occurring Fc polypeptide chain by no more thant 10 insertions, deletions, or substitutions of a single amino acid per every 100 amino acids of sequence. In some embodiments, such variations can be “heterodimerizing alterations” that facilitate the formation of heterodimers over homodimers. In referring to particular positions within an Fc polypeptide chain, the EU numbering system (Edelman et al. (1969), Proc. Natl. Acad. Sci. 63: 78-85) is used, as illustrated in the alignment of human IgG Fc polypeptide chains in Table 1 below.
“Heterodimerizing alterations” generally refer to alterations in the CH3 regions two different IgG heavy chains that facilitate the formation of heterodimeric heavy chain dimers, that is, dimerized heavy chains that do not have identical amino acid sequences. Heterodimerizing alterations can be asymmetric, that is, one heavy chain having a certain alteration can pair with another heavy chain having a different alteration. These alterations facilitate heterodimerization and disfavor homodimerization. One example of such paired heterodimerizing alterations are the so-called “knobs and holes” substitutions. See, e.g., U.S. Pat. No. 7,695,936 and US Patent Application Publication 2003/0078385, the portions of which describe such mutations are incorporated herein by reference. As meant herein, heavy chain-heavy chain pair that contains one pair of knobs and holes substitutions, contains one substitution in one heavy chain and another substitution in the other heavy chain. For example, the following knobs and holes substitutions have been found to increase heterodimer formation as compared with that found with unmodified heavy chains: 1) Y407T in one chain and T366Y in the other; 2) Y407A in one chain and T366W in the other; 3) F405A in one chain and T394W in the other; 4) F405W in one chain and T394S in the other; 5) Y407T in one chain and T366Y in the other; 6) T366Y and F405A in one chain and T394W and Y407T in the other; 7) T366W and F405W in one chain and T394S and Y407A in the other; 8) F405W and Y407A in one chain and T366W and T394S in the other; and 9) T366W in one polypeptide of the Fc and T366S, L368A, and Y407V in the other. As meant herein, mutations in an Fc polypeptide are denoted in the following way. The amino acid (using the one letter code) normally present at a given position in the CH3 region using the EU numbering system (which is presented in Edelman et al. (1969), Proc. Natl. Acad. Sci. 63: 78-85) is followed by the EU position, which is followed by the alternate amino acid that is present at that position. For example, Y407T means that the tyrosine normally present at EU position 407 is replaced by a threonine. For the sake of clarity, the EU system of numbering is illustrated in Table 1 below. Alternatively or in addition to such alterations, substitutions creating new disulfide bridges can facilitate heterodimer formation. See, e.g., US Patent Application Publication 2003/0078385, the portions of which describe such mutations are incorporated herein by reference. Such alterations in an IgG1 Fc region include, for example, the following substitutions: Y349C in one Fc-polypeptide chain and S354C in the other; Y349C in one Fc-polypeptide chain and E356C in the other; Y349C in one Fc-polypeptide chain and E357C in the other; L351C in one Fc-polypeptide chain and S354C in the other; T394C in one Fc-polypeptide chain and E397C in the other; or D399C in one Fc-polypeptide chain and K392C in the other. Similarly, substitutions changing the charge of a one or more residue, for example, in the CH3-CH3 interface, can enhance heterodimer formation as explained in WO 2009/089004, the portions of which describe such substitutions are incorporated herein by reference. Such substitutions are referred to herein as “charge pair substitutions,” and an Fc region containing one pair of charge pair substitutions contains one substitution in one heavy chain and a different substitution in the other. General examples of charge pair substitutions include the following: 1) K409D or K409E in one chain plus D399K or D399R in the other; 2) K392D or K392E in one chain plus D399K or D399R in the other; 3) K439D or K439E in one chain plus D356K or D356R in the other; and 4) K370D or K370E in one chain plus E357K or E357R in the other. In addition, the substitutions R355D, R355E, K360D, or K360R in both chains can stabilize heterodimers when used with other heterodimerizing alterations. Specific charge pair substitutions can be used either alone or with other charge pair substitutions. Specific examples of single pairs of charge pair substitutions and combinations thereof include the following: 1) K409E in one chain plus D399K in the other; 2) K409E in one chain plus D399R in the other; 3) K409D in one chain plus D399K in the other; 4) K409D in one chain plus D399R in the other; 5) K392E in one chain plus D399R in the other; 6) K392E in one chain plus D399K in the other; 7) K392D in one chain plus D399R in the other; 8) K392D in one chain plus D399K in the other; 9) K409D and K360D in one chain plus D399K and E356K in the other; 10) K409D and K370D in one chain plus D399K and E357K in the other; 11) K409D and K392D in one chain plus D399K, E356K, and E357K in the other; 12) K409D and K392D on one chain and D399K on the other; 13) K409D and K392D on one chain plus D399K and E356K on the other; 14) K409D and K392D on one chain plus D399K and D357K on the other; 15) K409D and K370D on one chain plus D399K and D357K on the other; 16) D399K on one chain plus K409D and K360D on the other; and 17) K409D and K439D on one chain plus D399K and E356K on the other. Any of these heterodimerizing alterations can be part of an immunoglobulin IgG heavy chain as described herein.
A “human” antibody or protein, as meant herein, is an antibody or protein encoded by a nucleic acid sequence of human origin. A human antibody or protein can be made in cultured non-human cells or in vivo in a transgenic organism into which a nucleic acid molecule encoding the human antibody or protein has been introduced. Alternatively, a human antibody or protein can be made in cultured human cells or in a human in vivo.
An “IgG antibody,” as meant herein, is an antibody that consists essentially of the immunoglobulin domains present in most naturally-occurring IgG antibodies, i.e., a immunoglobulin heavy chain comprising a heavy chain variable (VH) region, a first heavy chain constant (CH1) region, a hinge region, a second heavy chain constant (CH2) region, and a third heavy chain constant (CH3) region and a light chain comprising a light chain variable (VL) region and a light chain constant (CL) region. Numerous sequences of such immunoglobulin domains are reported throughout the scientific literature, e.g., in S
An “immunoglobulin heavy chain” refers to a heavy chain of an IgG, IgA, IgM, IgE, or IgD antibody or variants thereof containing not more than 40, 30, 25, 20, 15, 10, or 5 insertions, deletions, or substitutions of a single amino acid relative to an immunoglobulin heavy chain encoded by nucleic acid sequences originating in nature. An “immunoglobulin IgG heavy chain” is limited to heavy chains from IgG antibodies or variants thereof containing not more than 40, 30, 25, 20, 15, 10, or 5 insertions, deletions, or substitutions of a single amino acid relative to the amino acid sequence of an IgG heavy chain encoded by nucleic acid sequences originating in nature. An immunoglobulin heavy chain consists essentially of a number of distinct regions or domains including a VH region, a CH1 region, a hinge region, a CH2 region, and a CH3 region. In some other isotypes, i.e., IgM and IgA, additional regions are included downstream from the CH3 region. Immunoglobulin heavy chains and the regions included therein are generally described in, e.g., Carayannopoulos and Capra, Immunoglobulins: Structure and Function, pp. 283-314 in F
An “immunoglobulin light chain,” as meant herein, is a kappa or a lambda chain from a human antibody or an antibody from another species. Also included among immunoglobulin light chains, as meant herein, are proteins with no more than 20, 15, 10, or 5 insertions, deletions, and/or substitutions of a single amino acid relative to an immunoglobulin light chain encoded by nucleic acid sequences of natural origin. Immunoglobulin light chains are generally described in, e.g., Carayannopoulos and Capra, Immunoglobulins: Structure and Function, pp. 283-314 in F
An “immunoglobulin variable region,” as meant herein, is a VH or VL region, which can be of human origin or from another species. Immunoglobulin variable regions are generally described in, e.g., Carayannopoulos and Capra, Immunoglobulins: Structure and Function, pp. 283-314 in F
CDRs can be located in a VH region sequence in the following way. CDR1 starts at approximately residue 31 of the mature VH region and is usually about 5-7 amino acids long, and it is almost always preceded by a Cys-Xxx-Xxx-Xxx-Xxx-Xxx-Xxx-Xxx-Xxx (SEQ ID NO: 20) (where “Xxx” is any amino acid). The residue following the heavy chain CDR1 is almost always a tryptophan, often a Trp-Val, a Trp-Ile, or a Trp-Ala. Fourteen amino acids are almost always between the last residue in CDR1 and the first in CDR2, and CDR2 typically contains 16 to 19 amino acids. CDR2 may be immediately preceded by Leu-Glu-Trp-Ile-Gly (SEQ ID NO: 21) and may be immediately followed by Lys/Arg-Leu/Ile/VaVPhe/Thr/Ala-Thr/Ser/Ile/Ala. Other amino acids may precede or follow CDR2. Thirty two amino acids are almost always between the last residue in CDR2 and the first in CDR3, and CDR3 can be from about 3 to 25 residues long. A Cys-Xxx-Xxx almost always immediately precedes CDR3, and a Trp-Gly-Xxx-Gly (SEQ ID NO: 22) almost always follows CDR3.
Light chain CDRs can be located in a VL region in the following way. CDR1 starts at approximately residue 24 of the mature antibody and is usually about 10 to 17 residues long. It is almost always preceded by a Cys. There are almost always 15 amino acids between the last residue of CDR1 and the first residue of CDR2, and CDR2 is almost always 7 residues long. CDR2 is typically preceded by Ile-Tyr, Val-Tyr, Ile-Lys, or Ile-Phe. There are almost always 32 residues between CDR2 and CDR3, and CDR3 is usually about 7 to 10 amino acids long. CDR3 is almost always preceded by Cys and usually followed by Phe-Gly-Xxx-Gly (SEQ ID NO: 23).
A “linker,” as meant herein, is a peptide that links two polypeptides. A linker can be from 1-80 amino acids in length. In some embodiments, a linker can be 2-40, 3-30, or 3-20 amino acids long. In some embodiments, a linker can be a peptide no more than 14, 13, 12, 11, 10, 9, 8, 7, 6, or 5 amino acids long. In other embodiments, a linker can be 5-25, 5-15, 10-20, or 20-30 amino acids long. In other embodiments, a linker can be about, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acids long. In many cases, linkers lack free cysteine residues (i.e. not involved in disulfide bonds) and also do not contain N glycosylation sites (that is, Asn-Xxx-Ser/Thr, where X can be any amino acid except proline)
A “peptibody,” as meant herein, is one or more biologically active peptides fused to an Fc region. Shimamoto et al. (2012), mAbs 4(5): 586-591, the portions of which explain the structure of a peptibody and how to make it are incorporated herein by reference.
A “peptide,” as meant herein, is a polypeptide that consists of a short amino acid sequence, which may or may not be glycosylated and/or contain modified amino acids. A peptide can be from 2 to 75 amino acids long. In some embodiments, a peptide is 3-60, 3-50, 3-40, 3-30, or 3-20 amino acids long. In other embodiments, a peptide can be 5-25, 5-15, 10-20, or 20-30 amino acids long. In other embodiments, a peptide can be about, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acids long.
A “therapeutically effective amount” of a drug used to treat a disease is an amount that can reduce the severity of a disease, reduce the severity of one or more symptoms associated with the disease or its treatment, or delay the onset of more serious symptoms or a more serious disease that can occur with some frequency following the treated condition.
“Treatment” of any disease mentioned herein encompasses an alleviation of at least one symptom of the disease, a reduction in the severity of the disease, or the delay or prevention of disease progression to more serious symptoms that may, in some cases, accompany the disease or lead to at least one other disease. Treatment need not mean that the disease is totally cured. A useful therapeutic agent needs only to reduce the severity of a disease, reduce the severity of one or more symptoms associated with the disease or its treatment, or delay the onset of more serious symptoms or a more serious disease that can occur with some frequency following the treated condition. For example, if the disease were an inflammatory bowel disease, a therapeutic agent used as a treatment may reduce the number of distinct sites of inflammation in the gut or the total extent of the gut affected. It may reduce pain and/or swelling, reduce symptoms such as diarrhea, constipation, or vomiting, and/or prevent perforation of the gut. A patient's condition can be assessed by standard techniques such as an x-ray performed following a barium enema or enteroclysis, endoscopy, colonoscopy, and/or a biopsy. Suitable procedures vary according to the patient's condition and symptoms. Similarly, if the disease treated were systemic lupus erythematosus (SLE), disease activity could be evaluated using the SLEDAI index for scoring, as explained below.
Disclosed herein are bispecific proteins that bind to B7RP1 and BAFF and/or that can inhibit B7RP1-mediated T cell proliferation and BAFF-mediated B cell proliferation in vitro. The BAFF and B7RP1 proteins to which a bispecific protein as described herein binds can be human proteins and/or can be proteins from another species such as cynomolgus monkey, rhesus monkey, chimpanzee, mouse, and/or rabbit, among others. In some embodiments, a bispecific protein as described herein can, for example, bind to both human (Homo sapiens) and cynomolgus monkey (Macaca fascicularis) B7RP1 and BAFF proteins.
In some embodiments, these bispecific proteins can be bispecific IgG antibodies in which the B7RP1-binding portion and the BAFF-binding portion each consists essentially of an immunoglobulin IgG heavy chain and an immunoglobulin light chain. Thus, such a bispecific antibody contains two different immunoglobulin heavy chains and two different immunoglobulin light chains. Together, these two pairs of immunoglobulin heavy and light chains form a complete bispecific IgG antibody. Bispecific IgG antibodies are known in the art, and a number of other formats for bispecific antibodies are also known. See, e.g., Kontermann, Bispecific Antibodies: Developments and Current Perspectives, pp. 1-28 in B
In other embodiments, the bispecific proteins described herein can be fusion proteins comprising an antibody that binds to B7RP1, which comprises an immunoglobulin IgG heavy chain and an immunoglobulin light chain, and a peptide that binds to BAFF. The BAFF-binding peptide can be present in one or multiple copies, such as two, three, four, five, six, seven, eight, or up to 16 copies. The BAFF-binding peptide may bind to BAFF proteins from species such as mouse, cynomolgus monkey, and/or humans, among many other possible species. The antibody can be an anti-B7RP1 IgG antibody, optionally a human or humanized antibody that binds to human and/or cynomolgus monkey B7RP1. In some embodiments, a linker can be attached to the C terminus of the heavy chain of the anti-B7RP1 IgG antibody, followed by a first BAFF-binding peptide, another linker, and a second BAFF-binding peptide. A third, fourth, fifth, sixth, seventh, eighth, or up to sixteenth BAFF-binding peptide can follow these two, optionally interspersed with linkers. Alternatively or in addition, one, two, three, four, five, six, seven, or eight BAFF-binding peptides can be inserted elsewhere in the anti-B7RP1 antibody, for example at the N terminus of the immunoglobulin heavy chain or immunoglobulin light chain or in a loop region in the CH2 or CH3 region. The IgG antibody can be a mammalian antibody, such as a human or murine antibody. The anti-B7RP1 antibody can be a human or humanized IgG1, IgG2, IgG3, or IgG4 antibody. In such bispecific fusion proteins comprising an anti-B7RP1 IgG antibody, the bispecific protein can comprise a heavy chain comprising the amino acid sequence of SEQ ID NO:17 or SEQ ID NO:18 and an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:19. Variants comprising a heavy chain having an amino acid sequence containing no more than 30, 25, 20, 15, 10, 5, or 3 insertions, deletions, or substitutions of a single amino acid relative to SEQ ID NO: 17 or 18 are contemplated. Similarly, variants comprising an immunoglobulin light chain having an amino acid sequence containing no more 20, 15, 10, 8, 7, 5, or 3 insertions, deletions, or substitutions or a single amino acid relative SEQ ID NO:19 are contemplated. Such bispecific proteins can be tetramers comprising two polypeptides comprising the amino acid sequence of SEQ ID NO:17 or 18 or a variant thereof and two light chains comprising the amino acid sequence of SEQ ID NO:19 or a variant thereof.
A BAFF-binding peptide portion of a bispecific fusion protein as described above can comprise the amino acid sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. Such BAFF-binding peptides are described in U.S. Pat. No. 7,737,111, the relevant portions of which are incorporated herein by reference. In some embodiments, there may be one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen copies of such a BAFF-binding peptide present in the bispecific protein. A BAFF-binding peptide can be attached to the carboxy end of the anti-B7RP1 antibody, for example, via a linker. For example, the carboxy end of an anti-B7RP1 IgG antibody can be followed by a linker having, for example, the amino acid sequence of Gly-Gly-Gly-Gly (SEQ ID NO:4). Examples of other suitable linkers include Gly-Gly, Gly-Gly-Gly, Gly-Gly-Gly-Ser (SEQ ID NO:37), Gly-Gly-Gly-Pro (SEQ ID NO:38), Gly-Gly-Gly-Gln (SEQ ID NO:39), and Gly-Gly-Gly-Gly-Gly (SEQ ID NO:40), among many others. This linker can be followed by a BAFF-binding peptide. The BAFF-binding peptide can be followed by another linker comprising, for example, the amino acid sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:24. Other linker could also be used. This linker can be followed by another BAFF-binding peptide comprising, for example, the amino acid sequence of SEQ ID NO:1.
In the bispecific fusion proteins described immediately above or in the bispecific heterotetrameric IgG antibodies described above, a VL region can contain a CDR1, a CDR2, and a CDR3 comprising the amino acid sequences of SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, respectively. A VH region CDR1, CDR2, and CDR3 can comprise the amino acid sequences of SEQ ID NO:11, SEQ ID NO:12, and SEQ ID NO:13, respectively. In some embodiments, a VL region of the IgG antibody can comprise the amino acid sequence of SEQ ID NO:14 or a variant thereof, and the VH region can comprise the amino acid sequence of SEQ ID NO:15 or a variant thereof. Such variant sequences can comprise not more than 10 deletions, insertions of substitutions of a single amino acid per 100 amino acids relative to a reference sequence.
Provided herein are linkers having the amino acid sequences of SEQ ID NO:5, 6, or 7 that confer favorable physical properties on a protein that contains them. As shown in Example 1 below, the use of two particular linkers, i.e., those having the amino acid sequences of SEQ ID NO:6 and SEQ ID NO:7, had positive effects on properties such as expression, stability, and viscosity of a bispecific molecule. Thus, a variety of proteins containing these linkers may have such favorable properties as compared to similar proteins containing other linkers.
The bispecific proteins binding to BAFF and B7RP1 described herein can be used as therapeutics for a variety of indications, particularly conditions driven by autoantibodies and/or conditions mediated by both T cells and B cells. Such conditions include, for example, SLE, lupus, nephritis, ANCA-positive vasculitis, rheumatoid arthritis (RA), dermatomyositis, polymyositis, gastrointestinal diseases such as Crohn's disease, ulcerative colitis, and celiac disease, skin conditions such as pemphigus, pemphigoid, and subacute cutaneous lupus erythematosus (SCLE), diseases of the nervous system such as multiple sclerosis and chronic inflammatory demyelinating polyneuropathy (CIDP), neuromuscular diseases such as myasthenia gravis, diseases involving the kidneys such as Goodpasture's syndrome and glomerulonephritis, hematologic conditions such as autoimmune hemolytic anemia (AIHA), idiopathic thrombocytopenic purpura (ITP), and autoimmune neutropenia, liver conditions such as chronic active hepatitis and primary biliary cirrhosis, Sjogren's syndrome, systemic sclerosis, and endocrine conditions including Hashimoto's thyroiditis, Graves' disease, Addison's disease, and multiple endocrine autoimmune failure (commonly including diabetes, hypothyroidism, Addison's disease, and gonadal failure). A therapeutically effective amount of a bispecific protein as described herein can be administered to a patient suffering from any of these conditions to treat the condition.
In one embodiment, a bispecific protein that can inhibit BAFF-mediated B cell proliferation and B7RP1-mediated T cell proliferation can be used to treat a patient suffering from SLE. SLE is an autoimmune disease of unknown etiology marked by autoreactivity to nuclear self antigens. Its clinical manifestations are so diverse that it is questionable whether it is truly a single disease or a group of related conditions. Kotzin (1996) Systemic lupus erythematosus. Cell 85: 303-306; Rahman and Isenberg (2008), Systemic lupus erythematosus. N. Engl. J. Med. 358: 929-939. Symptoms can include the following: constitutional symptoms such as malaise, fatigue, fevers, anorexia, and weight loss; diverse skin symptoms including acute, transient facial rashes in adults, bullous disease, and chronic and disfiguring rashes of the head and neck; arthritis; muscle pain and/or weakness; cardiovascular symptoms such as mitral valve thickening, vegetations, regurgitation, stenosis, pericarditis, and ischemic heart disease, some of which can culminate in stroke, embolic disease, heart failure, infectious endocarditis, or valve failure; nephritis, which is a major cause of morbidity in SLE; neurological symptoms including cognitive dysfunction, depression, psychosis, coma, seizure disorders, migraine, and other headache syndromes, aseptic meningitis, chorea, stroke, and cranial neuropathies; hemotologic symptoms including leucopenia, thrombocytopenia, serositis, anemia, coagulation abnormalities, splenomegaly, and lymphadenopathy; and various gastrointestinal abnormalities. Id; Vratsanos et al., “Systemic Lupus Erythematosus,” Chapter 39 in Samter's Immunological Diseases, 6th Edition, Austen et al., eds., Lippincott Williams & Wilkins, Phiiladelphia, Pa., 2001. Severity of symptoms varies widely, as does the course of the disease. SLE can be deadly.
An SLE patient can be treated with a bispecific protein that inhibits BAFF and B7RP1 before, after, or concurrently with treatment using an existing therapy for SLE. Such existing therapies for SLE include corticosteroids such as prednisone, prednisolone, and methylprednisolone, antimalarials such as hydroxychloroquine, quinacrine, and chloroquine, retinoic acid, aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), cyclophosphamide, dehydroepiandrosterone, mycophenolate mofetil, azathioprine, chlorambucil, methotrexate, tacrolimus, dapsone, thalidomide, leflunomide, cyclosporine, belimumab, anti-CD20 antibodies such as rituximab, and fusion proteins such as abatacept.
The disease activity of SLE patients can be rated using an instrument such as the Systemic Lupus Erythrmatosus Disease Activity Index (SLEDAI), which provides a score for disease activity that takes into consideration the following symptoms, which are weighted according to severity: seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, vasculitis, arthritis, myositis, urinary casts, hematuria, proteinuria, pyuria, new rash, alopecia, mucosal ulcers, pleurisy, pericarditis, low complement, increased DNA binding, fever, thrombocytopenia, and leucopenia. Bombardier et al. (1992), Arthr. & Rheum. 35(6): 630-640, the relevant portions of which are incorporated herein by reference. The treatments described herein can be useful in lessening or eliminating symptoms of SLE as measured by SLEDAI. Methods of treatment described herein can improve a patient's SLEDAI score compared to a baseline value for the same patient prior to initiation of treatment with a bispecific protein as described herein.
Another method for assessing disease activity in SLE is the British Isles Lupus Assessment Group (BILAG) index, which is a disease activity assessment system for SLE patients based on the principle of the physician's intention to treat. Stoll et al. (1996), Ann. Rheum Dis. 55: 756-760; Hay et al. (1993), Q. J. Med. 86: 447-458. The portions of these references describing the BILAG are incorporated herein by reference. A BILAG score is assigned by giving separate numeric or alphabetic disease activity scores in each of eight organ-based systems, general (such as fever and fatigue), mucocutaneous (such as rash and alopecia, among many other symptoms), neurological (such as seizures, migraine headaches, and psychosis, among many other symptoms), musculoskeletal (such as arthritis), cardiorespiratory (such as cardiac failure and decreased pulmonary function), vasculitis and thrombosis, renal (such as nephritis), and hematological. Id. The treatments described herein can be useful in lessening or eliminating symptoms of SLE as measured by the BILAG index or in decreasing a patient's BILAG score as compared to a baseline value prior to the initiation of treatment with a bispecific protein as described herein.
A bispecific protein as described herein, which inhibits BAFF-mediated proliferation of B cells and B7RP1-mediated proliferation of T cells, could also be used to treat rheumatoid arthritis (RA). RA is a chronic disease with systemic symptoms, as well as symptoms relating specifically to the joints. Symptoms commonly include synovitis, leading to painful and swollen joints, and various laboratory abnormalities such as higher-than-normal levels of rheumatoid factor, anti-citrulline modified protein (anti-CCP) antibodies, and C-reactive protein (CRP) and an elevated erythrocyte sedimentation rate (ESR). Less common symptoms include various extra-articular symptoms involving, e.g., tendons, ligaments, blood vessels, the heart, and the lungs. Disease activity can be often measured using a variety of indices. See, e.g., Anderson et al. (2012), Arthritis care & Res. 64 (5): 640-647, the portions of which discuss such indices are incorporated herein by reference. Elements included in such scoring indices include the number of tender joints, the number of swollen joints, functional assessments, and various laboratory findings such as CRP, ESR, etc.
In some embodiments, a patient suffering from RA can be treated with a bispecific protein that inhibits BAFF-mediated B cell proliferation and B7RP1-mediated T cell proliferation before, after, or concurrently with treatment with a drug in current use for RA. Therapeutics currently in use for rheumatoid arthritis (RA) include non-steroidal anti-inflammatory drugs (NSAIDs) (such aspirin and cyclooxygenase-2 (COX-2) inhibitors), disease modifying anti-inflammatory drugs (DMARDs, such as methotrexate, leflunomide, and sulfasalazine), anti-malarials (such as hydroxychloroquine), cyclophosphamide, D-penicillamine, azathioprine, gold salts, tumor necrosis factor inhibitors (such as etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol), CD20 inhibitors such as rituximab, IL-1 antagonists such as anakinra, IL-6 inhibitors such as tocilizumab, inhibitors of Janus kinases (JAKs, such as tofacitinib), abatacept, and corticosteroids, among others.
A therapeutically effective amount of a bispecific protein as described herein, which inhibits BAFF-mediated proliferation of B cells and B7RP1-mediated proliferation of T cells, can also be used to treat an inflammatory bowel disease, such as Crohn's disease or ulcerative colitis. Crohn's disease is involves an abnormal inflammation of any portion of the alimentary tract from the mouth to the anus, although in most patients abnormal inflammation is confined to the ileocolic, small-intestinal, and colonic-anorectal regions. Typically, the inflammation is discontinuous. Common symptoms include abdominal pain, anorexia, weight loss, fever, diarrhea, fullness and/or tenderness in the right lower quadrant of the abdomen, constipation, vomiting, and perianal discomfort and discharge. Other possible symptoms include peripheral arthritis, growth retardation, episcleritis, aphthous stomatitis, erythema nodosum, pyoderma gangrenosum, kidney stones, impaired urinary dilution and alkalinization, malabsorption, and gallstones, among others. See e.g. Strober et al., Medical Immunology, 10th Edition, Section III, Ch. 35 (2001); Merck Manual of Diagnosis and Therapy, 17th Edition, Section 3, Ch. 31 (1999). Macrophages isolated from patients with Crohn's disease produce increased amounts of IL-12, IFNγ, TNFα, and other inflammatory cytokines.
Ulcerative colitis, though it is sometimes hard to distinguish from Crohn's disease, is distinct from Crohn's disease in several respects. First, it is generally limited to the colon while Crohn's disease may occur throughout the alimentary tract. Second, ulcerative colitis mainly involves inflammation only of the superficial layers of the bowel, unlike Crohn's disease in which the inflammation can penetrate all way through the wall of the bowel or other location in the alimentary tract. Finally, ulcerative colitis typically involves a continuous area of inflammation, rather than the discontinuous sites of inflammation typical of Crohn's disease. Like Crohn's disease, ulcerative colitis is found primarily in urban areas. Also, genetic factors likely play a role in ulcerative colitis since there is a familial aggregation of cases. Autoantibodies are observed in ulcerative colitis patients more often than Crohn's disease patients. The autoantibodies are often directed to colonic epithelial cell components. Among the most common are antineutrophil cytoplasmic antibodies with specificities for catalase, α-enolase, and lactoferrin. In some cases such antibodies cross react with colonic microorganisms.
In clinical trials, Crohn's disease activity is often scored using the Crohn's Disease Activity Index (CDAI). The CDAI provides a disease activity score based on eight factors including (1) the number of liquid or soft stools per day, (2) a patient rating of the amount of abdominal pain per day, (3) a patient rating of general well-being, (4) a patient report of other symptoms including arthritis, iritis, uveitis, erythema nodosum, pyoderma gangrenosum, ephthous stomatitis, anal fissure, fitula, or abscess, other fistula, or fever, (5) patient report of taking lomotil or other opiates for diarrhea, (6) abdominal mass, (7) hematocrit, and (8) body weight. See, e.g., Best et al. (1976), Gastroenterol. 70: 439-444, the relevant portions of which are incorporated herein by reference.
Symptoms of ulcerative colitis are variable. They may include diarrhea, tenesmus, abdominal cramps, blood and mucus in the stool, fever, and rectal bleeding. Toxic megacolon, a potentially life-threatening condition in which the colon is dilated beyond about 6 centimeters and may lose its muscular tone and/or perforate, may also occur. Other symptoms that may accompany ulcerative colitis include peripheral arthritis, ankylosing spondylitis, sacroiliitis, anterior uveitis, erythema nodosum, pyoderma gangrenosum, episcleritis, autoimmune hepatitis, primary sclerosing cholangitis, cirrhosis, and retarded growth and development in children.
In some embodiments a patient suffering from an inflammatory bowel disease (IBD), such as Crohn's disease or ulcerative colitis, can be treated with a bispecific protein that binds to BAFF and B7RP1 before, after, or concurrently with treatment with an existing therapy for IBD. Existing therapeutics for IBD include, for example, sulfasalazine, 5-aminosalicylic acid and its derivatives (such as olsalazine, balsalazide, and mesalamine), anti-TNF antibodies (including infliximab, adalimumab, golimumab, and certolizumab pegol), corticosteroids for oral or parenteral administration (including prednisone, methylprednisone, budesonide, or hydrocortisone), adrenocorticotropic hormone, antibiotics (including metronidazole, ciprofloxacin, or rifaximin), azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, tacrolimus, and thalidomide.
Provided herein are nucleic acids encoding a bispecific protein that can inhibit B7RP1-mediated T cell proliferation and BAFF-mediated B cell proliferation. For example, SEQ ID NO:52 encodes the VL region having the amino acid sequence of SEQ ID NO:14, and SEQ ID NO:53 encodes the VH region having the amino acid sequence of SEQ ID NO:15. Similarly, SEQ ID NOs:55 and 56 encode the amino acid sequences of SEQ ID NOs:17 and 18, respectively, which are polypeptides comprising the heavy chain of an anti-B7RP1 antibody fused to two BAFF-binding peptides. SEQ ID NO:57 encodes the light chain of an anti-B7RP1 antibody, which can be part of a hetero-tetrameric bispecific IgG antibody or a bispecific fusion protein, as described above. Any nucleic acid sequence encoding any amino acid sequence provided herein is contemplated. Similarly, nucleotide sequence variants encoding the amino acid sequence variants described above are also included within the ambit of the invention. More specifically, nucleotide sequences encoding amino acid sequences that vary by no more than 10 insertions, deletions, or substitutions of a single amino acid per 100 amino acids from amino acid sequences disclosed herein are contemplated.
Nucleic acid sequences encoding bispecific proteins described herein can be determined by one of skill in the art based on the amino acid sequences provided herein and knowledge in the art. Besides more traditional methods of producing cloned DNA segments encoding a particular amino acid sequence, companies such as DNA 2.0 (Menlo Park, Calif., USA) and BlueHeron (Bothell, Wash., USA), among others, now routinely produce chemically synthesized, gene-sized DNAs of any desired sequence to order, thus streamlining the process of producing such DNAs. Codon usage can be adjusted so as to optimize expression in the system of choice.
Nucleic acids encoding the bispecific proteins described herein can be inserted into vectors appropriate for the host cell in which the nucleic acid will be expressed. These nucleic acids can be introduced into the host cells by any of the methods well-known in the art. Host cells that can be used include bacteria, including Escherichia coli, yeast, including Saccharomyces cerevisiae or Pichia pastoris, insect cells including Spodoptera frugiperda cells, plant cells, and mammalian cells, including Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK) cells, monkey kidney cells, HeLa cells, human hepatocellular carcinoma cells, and 293 cells, among many others. These host cells can be cultured under conditions such that the introduced nucleic acids will be expressed, and the bispecific protein can be recovered from the culture supernatant or the cell mass.
Generally, the procedure used to introduce the nucleic acids into the host cells may depend upon the host cell into which the nucleic acids are to be introduced. Methods of introducing nucleic acids into bacteria are well-known in the art. For example, electroporation or calcium choride transformation are commonly used. Methods for introduction of nucleic acids into yeast are also well-known in the art and include, for example, transformation methods using lithium acetate and polyethylene glycol. Methods for introducing heterologous polynucleotides into mammalian cells are well known in the art and include, but are not limited to, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.
Expression vectors used in any of the host cells can contain sequences necessary for DNA replication, selection of host cells containing the vector, and expression of the exogenous nucleotide sequences. Such sequences can typically include one or more of the following nucleotide sequences: a promoter, one or more enhancer sequences, an origin of replication, a transcriptional termination sequence, a complete intron sequence containing a donor and acceptor splice site, a sequence encoding a leader sequence for polypeptide secretion, a ribosome binding site, a polyadenylation sequence, a polylinker region for inserting the nucleic acid encoding the polypeptide to be expressed, and a selectable marker element. Numerous expression vectors appropriate for expression in various host cells are known in the art and are commercially available.
Pharmaceutical compositions comprising the bispecific proteins described herein are provided. Such compositions can comprise a therapeutically effective amount of a bispecific protein with one or more additional components such as a physiologically acceptable carrier, excipient, or diluent. Such additional components can include buffers, carbohydrates, polyols, amino acids, chelating agents, stabilizers, and/or preservatives, among many possibilities. Many such additional components are described in, e.g., R
Dosing of the bispecific proteins described herein can be adjusted to achieve the desired effects. In many cases, repeated dosing will be required because of the chronic nature of the disease being treated. For example, a bispecific protein as described herein can be dosed twice per week, once per week, once every two, three, four, five, six, seven, eight, nine, or ten weeks, or once every two, three, four, five, or six months. The amount of the bispecific protein administered on each day that it is administered can be from about 0.0036 mg to about 700 mg. Alternatively, the dose can calibrated according to the estimated skin surface of a patient, and each dose can be from about 0.002 μg/m2 to about 350 mg/m2. In another alternative, the dose can be calibrated according to a patient's weight, and each dose can be from about 0.000051 mg/kg to about 10.0 mg/kg.
The bispecific proteins, or pharmaceutical compositions containing these molecules, can be administered by any feasible method. Therapeutics that comprise a protein will ordinarily be administered by a parenteral route, for example by injection, since oral administration, in the absence of some special formulation or circumstance, would lead to hydrolysis of the protein in the acid environment of the stomach. Subcutaneous, intramuscular, intravenous, intraarterial, intralesional, and peritoneal bolus injections are possible routes of administration. The bispecific proteins can also be administered via infusion, for example intravenous or subcutaneous infusion. Topical administration is also possible, especially for diseases involving the skin. Alternatively, the bispecific proteins can be administered through contact with a mucus membrane, for example by intra-nasal, sublingual, vaginal, or rectal administration or administration as an inhalant. Alternatively, certain appropriate pharmaceutical compositions comprising a bispecific protein can be administered orally.
Having described the invention in general terms above, the following examples are offered by way of illustration and not limitation.
The object of this series of experiments was to find a bispecific molecule that (1) inhibits BAFF-mediated B cell proliferation and B7RP1-mediated T cell proliferation, (2) is highly active in biological assays, and (3) has favorable biophysical properties. A number of schematic designs for the fusion of a peptide that binds human BAFF to an anti-human B7RP1 IgG antibody (anti-huB7RP1) are illustrated in
To determine which design had the best biophysical properties, while retaining biological activity, the bispecific molecules diagrammed in
In constructs P74293 and P74294, the linker between the two tandem copies of the BAFF-binding peptides in construct P71619 was modified. The amino acid sequences of the heavy chains of P74293 and P74294 are provided in SEQ ID NO:17 and SEQ ID NO:18, respectively. The immunoglobulin light chains of these constructs also have the amino acid sequence of SEQ ID NO:19.
Nucleic acids encoding the constructs described above were made as follows. Nucleic acids encoding the N-terminal portion of the N-terminal BAFF peptide fusions (P71617 and P71618), including two copies of the BAFF-binding peptide plus an immunoglobulin heavy or light chain variable region, were generated synthetically. These were ligated, through convenient restriction endonuclease sites, to nucleic acids encoding the immunoglobulin heavy or light chain constant region in appropriate vectors. Nucleic acids encoding the heavy chain constant region C-terminal fusions (P71619 and P71620), Fc-loop insertions (P71621 and P71623), and the Fc-loop insertion/C-terminal fusion (P71622) were all generated synthetically and ligated into a vector containing the heavy chain variable region through convenient restriction endonuclease sites.
The various bispecific constructs described above were expressed in both transiently transfected 293 cells and stably transfected CHO cells. The fusion proteins were purified and tested for biological activity. No differences were observed in proteins produced in these two different kinds host cells.
The BAFF inhibitory activities of the bispecific molecules were tested in a BAFF-mediated human primary B cell proliferation assay. In brief, human B cells were purified from peripheral blood mononuclear cells (PBMCs) using negative selection using a human B cell kit II from Miltenyi Biotec (Auburn, Calif.). About 105 purified B cells were cultured in 96 well microtiter plates in Minimal Essential Media (MEM) plus 10% heat inactivated fetal bovine serum (FBS) in the presence of 50 ng/ml human BAFF protein, 2 μg/ml goat F(ab′) 2 anti-human IgM (Jackson ImmunoResearch), and varying concentrations of one of the bispecific proteins described above at 37° C. in 5% CO2 for 48 hours. An anti-BAFF peptibody used as a positive control (“αBAFF,” which is a homodimer containing two polypeptide chains, each comprising two BAFF-binding peptides fused to an Fc polypeptide). The αBAFF molecule is described in detail in U.S. Pat. No. 7,259,137, and the amino acid sequence of one polypeptide chain of this homodimer is provided in SEQ ID NO:32. The portions of U.S. Pat. No. 7,259,137 describing αBAFF are incorporated herein by reference. Proliferation was measured by the uptake of radioactive 3H-thymidine during the last 18 hours of incubation. Results are shown in
The data in
The B7RP1 inhibitory activity of P71619, P74293, and P74294 was assayed using a human B7RP1-Fc-mediated T cell proliferation assay. Primary human T cells purified from PBMCs from healthy human donors using Pan T cell isolation kit from Miltenyi Biotec (Auburn, Calif.) and stimulated with plate-bound anti-CD3 (1 μg/mL) antibody and a B7RP1-Fc fusion protein (3 μg/mL) in the presence of varying concentrations of the bispecific proteins described above or an IgG2 anti-B7RP1 antibody (referred to herein as “αB7RP1”). 3H-thymidine was added to the cells after 48 hours, and incorporation of the 3H-thymidine was measured 24 hours later. All of the bispecific antibodies that were tested had similar IC50's, which were similar to that of αB7RP1 (
Three bispecific proteins, that is P71619, P74293, and P74294, were examined for properties relevant to their suitability as protein therapeutics. Protein titers of cultured host cells producing these proteins were determined. Stability of the proteins upon storage for two weeks at 40° C. was assessed by size exclusion chromatography (SEC). The percent of the protein remaining in the main peak after this storage was determined. Viscosity at 141-158 mg/mL was also measured. These data are reported in Table 2 below.
These data indicate that P74293 and P74294 were expressed at higher levels than P71619 and were also more stable and less viscous in the concentration range tested than P71619. Since the only difference between P71619 and the other two molecules lies in the linker between the two BAFF-binding peptides, these data indicate that the linkers in P74293 and P74294 (SEQ ID NO:6 and 7) conferred improved properties upon these molecules.
The pharmacokinetic properties of the bispecific molecules described were evaluated in mice. Male CD-1 mice were given a single intravenous (IV) dose (5 mg/kg) of the bispecific fusion proteins P71617, P71619, P71621, P71622, P74293, or P74294. Serum samples were collected before dosing and at 0.5, 2, 8, 24, 48, 72, 96, 168, 240, 336, 408, 504 hours after dosing. The concentration of the bispecific molecule in the serum was determined by two ELISA methods, one registering the presence of the Fc portion and one registering the presence of both the Fc portion and the BAFF-binding peptide portion. For the Fc portion measurement, a biotinylated anti-Fc antibody was used as capture reagent, and ALEXA FLUOR® 647-labeled anti-Fc antibody was used as the detection reagent. To detect the BAFF-binding portion and the Fc portion of the bispecific, a biotinylated BAFF protein was used as the capture reagent, and ALEXA FLUOR® 647-labeled anti-Fc antibody was used as the detection reagent. The bispecific proteins with two tandem copies of BAFF-binding petides fused to the N-terminus (P71617), C-terminus (P71619, P74293 and P74294) or CH3 domain (P71621) of the heavy chain have very similar PK profiles in mice.
To conduct preclinical studies in mice, a murine surrogate bispecific molecule that could bind to murine B7RP1 and murine BAFF (hereinafter, the “murine surrogate”) was constructed. The anti-huB7RP1 antibody used to construct the bispecific constructs described in Example 1 did not bind to murine B7RP1, while the BAFF-binding peptide used in these constructs did bind to both human and murine BAFF. Data not shown. The murine surrogate comprises an antagonistic IgG anti-murine B7RP1 antibody (called “anti-mB7RP1” herein), which was a chimera of mouse immunoglobulin constant regions and rat anti-murine B7RP1 immunoglobulin variable regions. The use of anti-mB7RP1 is described in Hu et al. (2009), J. Immunol. 182: 1421, where it is designated 1B7-V2. The murine surrogate has two copies of a BAFF-binding peptide (SEQ ID NO:1) fused via a short linker (five amino acids long) to the C-terminus of the immunoglobulin heavy chain of anti-mB7RP1. The two copies of the BAFF-binding peptide are separated by another linker that is 23 amino acids long. Nucleic acids encoding the heavy chain of the murine surrogate were made using overlap PCR to join nucleic acids encoding the BAFF-binding portion of αBAFF to the downstream end of nucleic acids encoding the heavy chain of 1B7-V2.
BAFF inhibition by the murine surrogate was evaluated in a BAFF-mediated B cell proliferation assay. Mouse B lymphocytes were isolated from C57BL/6 spleens by negative selection with MACS CD43 (ly-48) Microbeads according to the manufacturers instructions (Miltenyi Biotec, Auburn, Calif.). PBMC using a B cell isolation kit (Miltenyi Biotec, Auburn, Calif.). Purified B cells were stimulated with 0.1 μg/ml anti-IgM and 200 ng/ml BAFF in the presence of varying concentrations of the murine surrogate or αBAFF. B cell proliferation was measured by 3H-thymidine incorporation at day 4. The IC50's of the murine surrogate and αBAFF were 0.59 nM and 0.73 nM, respectively. See
To measure inhibition of B7RP1 binding to its receptor by the murine surrogate, mouse spleen cells were first activated to enhance their expression of the B7RP1 receptor by incubating them in microtiter wells coated with an anti-CD3 (5 μg/ml) antibody for 24 hours. The activated spleen cells were washed with phosphate buffered saline (PBS) and then incubated with 5 μg/ml biotinylated muB7RP1:Fc in the presence of varying concentrations of the murine surrogate at 4° C. for 30 minutes. The cells were washed and then stained with allophycocyanin (APC)-conjugated anti-mouse CD3 antibody and streptavidin-phycoerythrin (Streptavidin-PE) for an additional 20 minutes. The B7RP1-Fc binding to T cells was analyzed by flow cytometry. The IC50's of the murine surrogate and anti-mB7RP1 were 4.01 pM and 2.8 pM, respectively. See
The in vivo pharmacodynamic effects of the murine surrogate were evaluated in mice immunized with the sheep red blood cells (SRBC). In brief, BALB/c mice (8 weeks old) received a primary immunization on day 0 and a booster immunization on day 28 with 2×108 SRBC in 0.2 ml of PBS via intraperitoneal injection. The mice (n=5 for each molecule) were treated twice per week from day 0 to day 33 with one of the following molecules at 5 mg/kg: the murine surrogate; αBAFF; anti-mB7RP1; or murine IgG1. Mice treated with SBRC, but not receiving another treatment, served as positive controls. The mice were sacrificed on day 34, and serum and spleens were collected.
To measure the proportion of B cells and memory T cells in the spleen, spleen cells were harvested by grinding the spleen tissue through a cell strainer. The spleen cells were preincubated with unlabelled anti CD16/32 to block the nonspecific binding of antibodies to Fc gamma receptors (FcγR). The proportion of B cells was determined by staining with PE-labeled anti-B220 (which is expressed on B cells). The proportion of memory T cells cells (CD44hiCD62LloCD4 T cells) was determined by staining with FITC-conjugated anti-CD44, PE-conjugated anti-CD62L, APC-conjugated anti-CD4 and PerCP-conjugated anti-CD3. All staining antibodies were purchased from BD Bioscience (San Diego, Calif.). For both B and T cell determinations, flow cytometry was performed with a FACSCALIBUR™ (BD Bioscience, San Jose, Calif.) flow cytometer, and the data was analyzed using FLOWJO® (TreeStar Inc., Ashland, Oreg.) software for analysis of flow cytometry data. Results are shown in
To measure levels of anti-SBRC antibodies in serum, microtiter plates coated with 10 μg/ml soluble SRBC antigen were incubated for two hours at room temperature with diluted serum from treated mice. Bound SRBC-specific Ig from the serum was detected with HRP-conjugated polyclonal goat anti-mouse IgG and IgM antibodies (Southern Biotech, Birmingham, Ala.). The substrate reaction was performed using SUREBLUE™ TMB microwell peroxidase substrate (KPL, Gaibersburg, Md.) according to the manufacturer's instructions, and the optical density was read using a Spectrum Max microplate reader (Molecular Devices). As a positive control, serial dilutions of a mixture of sera from SRBC-immunized mice without any treatment was added to each plate, and a standard curve was constructed from the readings from these wells. Levels of anti-SBRC antibodies of other samples are reported in
The percentage of spleen cells that are B cells was reduced in mice treated with the murine surrogate as compared to the percentage observed in mice treated with murine IgG1.
The impact of murine surrogate on disease was evaluated in the NZB/W F1 lupus model. Female NZB/W F1 mice (4.5 month old, n=20) were treated with 5 mg/kg murine surrogate (MW≅160 KDa), 4.68 mg/kg anti-mB7RP1 (MW≅150 KDa), 1.88 mg/kg αBAFF (MW≅64 KDa), a combination of αBAFF (1.88 mg/kg) and anti-mB7RP1 (4.68 mg/kg), or murine IgG1 (15 mg/kg; an isotype control) or phosphate buffered saline (PBS) (as negative controls) twice per week by intraperitoneal injection for 18 weeks. Proteinuria was measured in urine using ALBUSTIX® (Bayer, Elkhart, Ind.) every two weeks starting at 5 months of age. The incidence of proteinuria was expressed as the percentage of mice with urine protein at a concentration of at least 300 mg/dl in two consecutive measurements. Serum anti-dsDNA IgG level was measured by ELISA. At 12 months of age, none of the mice treated with the murine surrogate developed proteinuria. In contrast, 100% of mice treated with murine IgG1 or PBS exhibited proteinuria, and about 60% and 35% of mice treated with anti-mB7RP1 and αBAFF, respectively, developed proteinuria.
This application claims the benefit of U.S. Provisional Patent Application 61/780,260, filed Mar. 13, 2013, the contents of which are incorporated herein by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3773919 | Boswell et al. | Nov 1973 | A |
| 4399216 | Axel et al. | Aug 1983 | A |
| 4496689 | Mitra | Jan 1985 | A |
| 4619794 | Hauser | Oct 1986 | A |
| 4740461 | Kaufman | Apr 1988 | A |
| 4816397 | Boss et al. | Mar 1989 | A |
| 4816567 | Cabilly et al. | Mar 1989 | A |
| 4892538 | Aebischer et al. | Jan 1990 | A |
| 4912040 | Kaufman et al. | Mar 1990 | A |
| 4946778 | Ladner et al. | Aug 1990 | A |
| 4959455 | Clark et al. | Sep 1990 | A |
| 4970154 | Chang | Nov 1990 | A |
| 5011472 | Aebischer et al. | Apr 1991 | A |
| 5106627 | Aebischer et al. | Apr 1992 | A |
| 5151510 | Stec et al. | Sep 1992 | A |
| 5223409 | Ladner et al. | Jun 1993 | A |
| 5260203 | Ladner et al. | Nov 1993 | A |
| 5338665 | Schatz et al. | Aug 1994 | A |
| 5432018 | Dower et al. | Jul 1995 | A |
| 5498530 | Schatz et al. | Mar 1996 | A |
| 5514582 | Capon et al. | May 1996 | A |
| 5530101 | Queen et al. | Jun 1996 | A |
| 5545806 | Lonberg et al. | Aug 1996 | A |
| 5545807 | Surani et al. | Aug 1996 | A |
| 5569825 | Lonberg et al. | Oct 1996 | A |
| 5580756 | Linsley et al. | Dec 1996 | A |
| 5585089 | Queen et al. | Dec 1996 | A |
| 5593676 | Bhat et al. | Jan 1997 | A |
| 5593875 | Wurm et al. | Jan 1997 | A |
| 5625126 | Lonberg et al. | Apr 1997 | A |
| 5625825 | Rostoker et al. | Apr 1997 | A |
| 5633425 | Lonberg et al. | May 1997 | A |
| 5653975 | Baetge et al. | Aug 1997 | A |
| 5661016 | Lonberg et al. | Aug 1997 | A |
| 5676954 | Brigham | Oct 1997 | A |
| 5679559 | Kim et al. | Oct 1997 | A |
| 5693761 | Queen et al. | Dec 1997 | A |
| 5693762 | Queen et al. | Dec 1997 | A |
| 5733731 | Schatz et al. | Mar 1998 | A |
| 5770429 | Lonberg et al. | Jun 1998 | A |
| 5789650 | Lonberg et al. | Aug 1998 | A |
| 5814318 | Lonberg et al. | Sep 1998 | A |
| 5874299 | Lonberg et al. | Feb 1999 | A |
| 5877397 | Lonberg et al. | Mar 1999 | A |
| 5922545 | Mattheakis et al. | Jul 1999 | A |
| 5969102 | Bram et al. | Oct 1999 | A |
| 6180370 | Queen et al. | Jan 2001 | B1 |
| 6323323 | Sledziewski et al. | Nov 2001 | B1 |
| 6331415 | Cabilly et al. | Dec 2001 | B1 |
| 6403770 | Yu et al. | Jun 2002 | B1 |
| 6521749 | Ling et al. | Feb 2003 | B1 |
| 6869605 | Browning et al. | Mar 2005 | B2 |
| 6984720 | Korman et al. | Jan 2006 | B1 |
| 7030225 | Tamatani et al. | Apr 2006 | B1 |
| 7045615 | Tamatani et al. | May 2006 | B2 |
| 7112655 | Tamatani et al. | Sep 2006 | B1 |
| 7118872 | Beltzer et al. | Oct 2006 | B2 |
| 7125551 | Kroczek | Oct 2006 | B2 |
| 7132099 | Kroczek | Nov 2006 | B2 |
| 7196175 | Tamatani et al. | Mar 2007 | B2 |
| 7217792 | Tamatani et al. | May 2007 | B2 |
| 7226909 | Tamatani et al. | Jun 2007 | B2 |
| 7247612 | Tamatani et al. | Jul 2007 | B2 |
| 7259137 | Min et al. | Aug 2007 | B2 |
| 7259147 | Tamatani et al. | Aug 2007 | B2 |
| 7259247 | Kroczek | Aug 2007 | B1 |
| 7271245 | Felding-Habermann et al. | Sep 2007 | B2 |
| 7279560 | Tamatani et al. | Oct 2007 | B2 |
| 7294473 | Tamatani et al. | Nov 2007 | B2 |
| 7306800 | Kroczek | Dec 2007 | B2 |
| 7317089 | Kikly | Jan 2008 | B2 |
| 7435796 | Yoshinaga | Oct 2008 | B1 |
| 7521532 | Dunussi-Joannopoulos et al. | Apr 2009 | B2 |
| 7601813 | Ling et al. | Oct 2009 | B2 |
| 7695936 | Carter et al. | Apr 2010 | B2 |
| 7708993 | Yoshinaga et al. | May 2010 | B2 |
| 7728109 | Kikly | Jun 2010 | B2 |
| 7737111 | Min et al. | Jun 2010 | B2 |
| 7868140 | Siu et al. | Jan 2011 | B2 |
| 7928074 | Khare | Apr 2011 | B2 |
| 8062906 | Beltzer et al. | Nov 2011 | B2 |
| 8143380 | Walker et al. | Mar 2012 | B2 |
| 8507426 | Min et al. | Aug 2013 | B2 |
| 8557243 | Barbas, III | Oct 2013 | B2 |
| 8624010 | Yoshinaga | Jan 2014 | B1 |
| 8981071 | Siu et al. | Mar 2015 | B2 |
| 9458246 | Hsu | Oct 2016 | B2 |
| 20020115831 | Tamatani et al. | Aug 2002 | A1 |
| 20020151685 | Tamatani et al. | Oct 2002 | A1 |
| 20020156242 | Tamatani et al. | Oct 2002 | A1 |
| 20020177191 | Kroczek | Nov 2002 | A1 |
| 20020182667 | Kroczek | Dec 2002 | A1 |
| 20030059937 | Ruben et al. | Mar 2003 | A1 |
| 20030078385 | Arathoon et al. | Apr 2003 | A1 |
| 20030083472 | Tamatani et al. | May 2003 | A1 |
| 20040054158 | Ling et al. | Mar 2004 | A1 |
| 20040073012 | Tamatani et al. | Apr 2004 | A1 |
| 20040120945 | Tamatani et al. | Jun 2004 | A1 |
| 20040132658 | Tamatani et al. | Jul 2004 | A1 |
| 20040146506 | Tamatani et al. | Jul 2004 | A1 |
| 20040151669 | Tamatani et al. | Aug 2004 | A1 |
| 20040151718 | Tamatani et al. | Aug 2004 | A1 |
| 20040151720 | Tamatani et al. | Aug 2004 | A1 |
| 20040229788 | Tamatani et al. | Nov 2004 | A1 |
| 20050261489 | Kroczek | Nov 2005 | A1 |
| 20060084608 | Beltzer et al. | Apr 2006 | A1 |
| 20060099635 | Ling et al. | May 2006 | A1 |
| 20080152651 | Yoshinaga | Jun 2008 | A1 |
| 20080166352 | Siu et al. | Jul 2008 | A1 |
| 20080260737 | Ponce et al. | Oct 2008 | A1 |
| 20090110676 | Mackay et al. | Apr 2009 | A1 |
| 20090148442 | Ponce, Jr. et al. | Jun 2009 | A1 |
| 20090208504 | Yoshinaga | Aug 2009 | A1 |
| 20090281286 | Gregg et al. | Nov 2009 | A1 |
| 20110014189 | Soula et al. | Jan 2011 | A1 |
| 20110059068 | Yoshinaga et al. | Mar 2011 | A1 |
| 20110104757 | Siu et al. | May 2011 | A1 |
| 20110117093 | Ruben et al. | May 2011 | A1 |
| 20160024225 | Hsu et al. | Jan 2016 | A1 |
| 20170066845 | Hsu et al. | Mar 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| 0 036 676 | Sep 1981 | EP |
| 0 058 481 | Aug 1982 | EP |
| 0 088 046 | Sep 1983 | EP |
| 0 133 988 | Mar 1985 | EP |
| 0 143 949 | Jun 1985 | EP |
| 0 154 316 | Sep 1985 | EP |
| 0 526 452 | Feb 1993 | EP |
| 0 401 384 | Mar 1996 | EP |
| 0 784 680 | Jul 1997 | EP |
| 0 869 180 | Oct 1998 | EP |
| 0 939 804 | Sep 1999 | EP |
| 0 984 023 | Mar 2000 | EP |
| 1 125 585 | Aug 2001 | EP |
| 1 374 902 | Jan 2004 | EP |
| 1 502 920 | Feb 2005 | EP |
| 1 218504 | Jul 2007 | EP |
| 1 900 816 | Mar 2008 | EP |
| 2004-509615 | Apr 2004 | JP |
| 2004-525621 | Aug 2004 | JP |
| 2006-521085 | Sep 2006 | JP |
| 2008-505928 | Feb 2008 | JP |
| 2008-514201 | May 2008 | JP |
| 2009-501549 | Jan 2009 | JP |
| 2009-504191 | Feb 2009 | JP |
| 2009-515903 | Apr 2009 | JP |
| 2010-534212 | Nov 2010 | JP |
| WO-1988001649 | Mar 1988 | WO |
| WO-1990014363 | Nov 1990 | WO |
| WO-1991010425 | Jul 1991 | WO |
| WO-1992003918 | Mar 1992 | WO |
| WO-1992022646 | Dec 1992 | WO |
| WO-1993012227 | Jun 1993 | WO |
| WO-1993015722 | Aug 1993 | WO |
| WO-1994020069 | Sep 1994 | WO |
| WO-1995011308 | Apr 1995 | WO |
| WO-1996040958 | Dec 1996 | WO |
| WO-1996040987 | Dec 1996 | WO |
| WO-1998015833 | Apr 1998 | WO |
| WO-1998018921 | May 1998 | WO |
| WO-1998024884 | Jun 1998 | WO |
| WO-1998024893 | Jun 1998 | WO |
| WO-1998027114 | Jun 1998 | WO |
| WO-1998038216 | Sep 1998 | WO |
| WO-1998055620 | Dec 1998 | WO |
| WO-1998055621 | Dec 1998 | WO |
| WO-1999011791 | Mar 1999 | WO |
| WO-1999012964 | Mar 1999 | WO |
| WO-1999015553 | Apr 1999 | WO |
| WO-1999025044 | May 1999 | WO |
| WO-1999035170 | Jul 1999 | WO |
| WO-1999062951 | Dec 1999 | WO |
| WO-2000024782 | May 2000 | WO |
| WO-2000040716 | Jul 2000 | WO |
| WO-2000046240 | Aug 2000 | WO |
| WO-2000047740 | Aug 2000 | WO |
| WO-2000056772 | Sep 2000 | WO |
| WO-2000067034 | Nov 2000 | WO |
| WO-2000068378 | Nov 2000 | WO |
| WO-2001002440 | Jan 2001 | WO |
| WO-2001009187 | Feb 2001 | WO |
| WO-2001012658 | Feb 2001 | WO |
| WO-2001021796 | Mar 2001 | WO |
| WO-2001064704 | Sep 2001 | WO |
| WO-2001085782 | Nov 2001 | WO |
| WO-200202641 | Jan 2002 | WO |
| WO-2002004364 | Jan 2002 | WO |
| WO-2002008279 | Jan 2002 | WO |
| WO-2002016411 | Feb 2002 | WO |
| WO-2002016412 | Feb 2002 | WO |
| WO-2002044364 | Jun 2002 | WO |
| WO-2004043989 | May 2004 | WO |
| WO-2004106380 | Dec 2004 | WO |
| WO-2006003999 | Jan 2006 | WO |
| WO-2006010057 | Jan 2006 | WO |
| WO-2006036834 | Apr 2006 | WO |
| WO-2007011941 | Jan 2007 | WO |
| WO-2007024715 | Mar 2007 | WO |
| WO-2009015345 | Jan 2009 | WO |
| WO-2009089004 | Jul 2009 | WO |
| WO-2009088805 | Dec 2009 | WO |
| WO-2012162561 | May 2013 | WO |
| WO-2013158577 | Oct 2013 | WO |
| WO-2014144600 | Sep 2014 | WO |
| WO-2016039801 | Mar 2016 | WO |
| Entry |
|---|
| Perl A. Curr Opin Rheumatol. Sep. 2009 ; 21(5): 443-447. |
| Bartoloni et al. Arthritis Care & Research vol. 63, No. 2, Feb. 2011, pp. 178-183. |
| Coca et al. Curr Opin Rheumatol 2012, 24:451-456. |
| Sellam et al. Ann Rheum Dis 2007; 66:790-797. |
| Vossenkämper et al. Clinical and Experimental Immunology 2011; 167: 7-14. |
| Toro-Domínguez et al. Arthritis Research & Therapy 2014; 16(6): 489; 8 pages. |
| Abaza et al., Effects of amino add substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: Demonstration with region 94-100 (antigenic site 3) of myoglobin, J. Protein Chem., 11(5): 433-44 (1992). |
| Abrams et al., Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells, J Exp Med., 192(5): 681-94 (2000). |
| Abrams et al., CTLA4Ig-mediated blockade of T-cell costimulation in patients with Psoriasis vulgaris, J. Clin. Invest., 103(9): 1243-52 (1999). |
| Accession No. AI614037, EMBL Database, Mus musculus cDNA clone 5′ similar to TR:075144 KIAA0653 protein (Apr. 26, 1999). |
| Adamczyk et al., Application of surface plasmon resonance toward studies of low-molecular-weight antigen-antibody binding interactions, Methods, 20(3): 319-28 (2000). |
| Adamczyk et al., Surface plasmon resonance (SPR) as a tool for antibody conjugate analysis, Bioconjugate Chem., 10: 1032-37 (1999). |
| Adames et al., The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice, Nature, 318: 533-8 (1985). |
| Alexander et al., Expression of the c-myc oncogene under control of an immunoglobulin enhancer in E mu-myc transgenic mice, Mol. Cell. Biol., 7(4): 1436-44 (1987). |
| Altschul et al., Basic local alignment search tool, J. Molec. Biol., 215: 403-10 (1990). |
| Anderson et al., Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res. 64 (5): 640-7 (2012). |
| Aruffo et al, Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system, Proc. Natl. Acad. Sci. USA, 84: 8573-7 (1987). |
| Attwood et al., Genomics: The babel of bioinformatics, Science, 290: 471-3 (2000). |
| Ausubel et al., Current Protocols in Molecular Biology, Green Publishers, Inc. and Wiley and Sons, N.Y. (1994) [Table of Contents Only]. |
| Beck et al., Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 10: 345-52 (2010). |
| Benoist et al., In vivo sequence requirements of the SV40 early promoter region, Nature, 290(5804): 304-10 (1981). |
| Best et al., Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study, Gastroenterol. 70: 439-44 (1976). |
| Blaher et al., T cell response to grass pollen allergens: Correlation with skin test reactivity and serum IgE levels, Immunol. Cell Biol., 73: 17-22 (1995). |
| Blazar et al., Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host diseases lethality in part via direct effects on CD4+ and CD8+ T Cells, J. Immunol., 157: 3250-9 (1996). |
| Boerner et al., Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes, J. Immunol., 147(1): 86-95 (1991). |
| Bombardier et al., Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE, Arthr. & Rheum. 35(6): 630-40 (1992). |
| Bowie et al., Deciphering the message in protein sequences: Tolerance to amino acid substitutions, Science, 247: 1306-10 (1990). |
| Brinster et al., Regulation of metallothionein-thymidine kinase fusion plasmids injected into mouse eggs, Nature, 296(5852): 39-42 (1982). |
| Brodie et al., LICOS, aprimordial costimulatory ligand, Curr. Biol. 10(6): 333-6 (2000). |
| Bruggemann et al., Designer mice: The production of human antibody repertoires in transgenic animals, Year Immun., 7: 33-40 (1993). |
| Brunat et al., A new member of the immunoglobulin superfamily-CTLA-4, Nature, 328: 267-70 (1987). |
| Burton et al., Human antibody effector function, Adv. Immunol., 51:1-84 (1992). |
| Carillo et al., The multiple sequence alignment problem in biology, SIAM J. Appl. Math., 48: 1073 (1988). |
| Casset et la., A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochem. Biophys. Res. Commun. 307(1): 198-205 (2002). |
| Chang et al., B Cell Activating Factor (BAFF) and T Cells Cooperate to Breach B Cell Tolerance in Lupus-Prone New Zealand (NZB) Mice, PLoS One, 5(7):e11691 (2010). |
| Cheema et al., Elevated Serum B Lymphocyte Stimulator Levels in Patients With Systemic Immune—Based Rheumatic Diseases, Arthr. & Rheum. 44(6):1313-19. (2001). |
| Cheema et al., Increased B Lymphocyte Stimulator (BlySTM) Protein in HIV-Patients: Correlation with Anti-Cardiolipin (aCL) and Anti-Phospholipid (aPL) Autoantibodies, abstract (2002). |
| Chen et al., Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus, Int. Immunol., 5(6): 647-56 (1993). |
| Chen et al., Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matered Fab in complex with antigen. J. Mol. Biol. 293: 865-81 (1999). |
| Chirinos-Rojas et al., A Phage-Displayed Mimotope Inhibits Tumour Necrosis Factor-Induced Cytotoxicity More Effectively Than the Free Mimotope, Immunology, 96:109-13 (1999). |
| Chu et al., SV40 DNA transfection of cells in suspension: analysis of efficiency of transcription and translation of T-antigen, Gene, 13(2):197-202 (1981). |
| Cole et al., The EBV-hybridoma technique and its application to human lung cancer, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985). |
| Colman et al., Effects of amino acid sequence changes on antibody-antigen interactions, Res. Immunol., 145(1): 33-6 (1994). |
| Coyle et al., The CD28-related molecule ICOS is required for effective T cell-dependent immune responses, Immunity, 13(1): 95-105 (2000). |
| Coyle et al., The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function, Nat. Immunol., 2: 203-9 (2001). |
| Creighton (Ed.), Proteins, Structures and Molecular Principles, Freeman and Company, New York, TOC (1984). |
| Cwirla et al., Peptide Agoinist of the Thrombopoietin Receptor as Potent as the Natural Cytokine, Science, 276:1696-9 (1997). |
| Dai et al., The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection, Curr. Opin. Immunol., 11(5): 504-8 (1999). |
| Dariavach et al., Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains, Eur. J. Immunol., 18: 1901-5 (1988). |
| Database EMBL—Homo sapiens mRNA for KIAA0653 protein, partial cds.—EBI Accession No. AB014553 (Feb. 6, 1999). |
| Database EMBL—vg32f09.r1 Soares mouse mammary gland NbMMG Mus muscu/us cDNA clone IMAGE:863081.5, mRNA sequence—EMBL Accession No. AA510455 (Jul. 9, 1997). |
| Database EMBL—yg34c12.r1 Soares infant brain 1 NIB Homo sapiens cDNA clone IMAGE:34465.5, mRNA sequence—EBI Accession No. R23544 (Apr. 23, 1995). |
| Database UNIPROT, O'Regan et al., ICOS ligand—UNIPROT Accession No. 042404 (Jan. 1, 1998). |
| Database UNIPROT, Wang et al., ICOS ligand precursor (B7 homolog 2) (B7-H2) (B7-like protein G150) (B7-related protein 1) (P7RP-1) (CD275 antigen)—UNIPROT Accession No. 075144 (Jul. 15, 1999). |
| Davidson, The rationale for BAFF inhibition in systemic lupus erythematosus, The rationale for BAFF Inhibition in Systemic Lypus Erythematosus, Curr. Rheum. Rept., 14 (4):295-302 (2012). |
| Davis et at., Basic Methods in Molecular Biology, Elsevier (1986) [Table of Contents]. |
| Dayhoff et al., A model of evolutionary change in proteins, Atlas Protein Seq. Struct, 5: Supp. 3 (1978). |
| DeBoer et al., The tac promoter: A functional hybrid derived from the trp and lac promoters, Proc. Natl Acad. Sci. USA, 8: 21-5 (1983). |
| Del Prete et al., IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants, J. Immunol. 140(12): 4193-8 (1988). |
| DePascalis, Grafting of abbreviated complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody, J. Immunol., 169: 3076-84 (2002). |
| Desmyter et al., Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J. Biol. Chem. 276: 26285-90 (2001). |
| Devareaux et al., A comprehensive set of sequence analysis programs for VAX, Nucl. Acids Res. 12: 387 (1984). |
| Devlin et al., Random Peptide Libraries: A Source of Specific Protein Binding Molecules, Science, 249:404-6 (1990). |
| Dong et al., Regulation of immune and autoimmune responses by ICOS. J. Autoimmun. 21: 255-60 (2003). |
| Dwyer et al., The use of concanavalin A to study the immunoregulation of human T cells. Clin. Exp. Immunol., 46:237-49 (1981). |
| Edelman et al., The covalent structure of an entire gammaG immunoglobulin molecule. Proc. Natl. Acad. Sci. 63: 78-85 (1969). |
| Edgar, T cell immunodeficiency, J. Clin. Pathol., 61(9): 988-93 (2008). |
| Engels et al,. Gene synthesis, Angew. Chem. Intl. Ed., 28: 716-34 (1989). |
| Eppstein et al., Biological activity of liposome-encapsulated murine interferon .gamma. is mediated by a cell membrane receptor, Proc. Natl. Acad. Sci. USA, 62: 3688-92 (1985). |
| European Patent Office, European Search Report and Written Opinion for EP07019762.9 dated Dec. 5, 2008. |
| European Patent Office, European Search Report and Written Opinion for EP10178373.6 dated Dec. 20, 2010. |
| European Patent Office, Supplementary Partial European Search Report for EP02769739.0 dated Aug. 2, 2005. |
| European Search Report, EP 14180109.2, dated May 13, 2015. |
| Fick et al., Immunotherapy approach to allergic disease, Immunopharmacol., 48(3):7-10 (2000). |
| Fishwild et al., High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice, Nat. Biotechnol., 14(7): 845-51 (1996). |
| Francis, Protein modification and fusion proteins, Focus Growth Factors, 3: 4-10 (1992). |
| Freeman et al., B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells, J. Immunol., 143: 2714-22 (1989). |
| Freeman et al., Cloning of B7-2: A CTLA-4 counter-receptor that costimuates human T cell proliferation, Science, 262: 909-11 (1993). |
| Freeman et al., Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production, J. Exp. Med., 178: 2185-92 (1993). |
| Freeman et al., Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte, J. Exp. Med., 174: 625-31 (1991). |
| Frisque et al., Infectivity of the DNA from four isolates of JC virus, Virology, 32(2): 476-82 (1973). |
| Goeddel, Systems for heterologous gene expression, Meth. Enzymol., 185: 3-7 (1990) [Table of Contents]. |
| Graham et al., A new technique for the assay of infectivity of human adenovirus 5 DNA, Virology, 52(2): 456-67 (1973). |
| Gribskov et al., Sequence analysis primer, Stockton Press, N.Y. (1991) [Table of Contents]. |
| Griffin et al., Computer analysis of sequence data, Part 1, Humana Press, N.J. (1994) [Table of Contents]. |
| Gross et al., TACT and BCMA are Receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease, Nature, 404:995-9 (2000). |
| Gross et al., The murine homologue of the T lymphocyte antigen CD28, J. Immunol., 144:3201-10 (1990). |
| Grosschedl et al., Introduction of a mu immunoglobulin gene into the mouse germ line: Specific expression in lymphoid cells and synthesis of functional antibody, Cell, 38(3):647-58 (1984). |
| Gruss et al., Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas, Blood, 85:3378-3404 (1995). |
| Hammer et al., Diversity of alpha-fetoprotein gene expression in mice is generated by a combination of separate enhancer elements, Science, 235(4784): 53-8 (1987). |
| Hanahan, Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes, Nature, 315(6015): 115-22 (1985). |
| Harding et al., Class switching in human immunoglobulin transgenic mice, Ann. N.Y. Acad. Sci., 764: 536-46 (1995). |
| Hatzoglou et al., TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, and TRAF3 and Activates NF-KB, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activated Protein Kinase, J. Immunol. 165:1322-30 (2000). |
| Hay et al., the BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q. J. Med. 86: 447-58 (1993). |
| Heany et al., Severe asthma treatment: need for characterizing patients, Lancet, 365: 974-6 (2005). |
| Henikoff et al., Amino acid substitution matrices from protein blocks, Proc. Natl. Acad. Sci. USA, 89: 10915-19 (1992). |
| Henry et al., Cloning, structural analysis and mapping of the B30 and B7 multigenic families to the major histocompatibility complex (MMC) and other chromosomal regions, Immunogenetics, 46: 383-95 (1997). |
| Holliger et al., ‘Diabodies’: Small Bivalent and Bispecific Antibody Fragments, Proc. Natl. Acad. Sci. 90:6444-6448 (1993). |
| Holm et al., Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1, Mol. Immunol., 44(6): 1075-84 (2007). |
| Hoogenboom et al., By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro, J. Mol. Biol., 227(2): 381-8 (1992). |
| Houghten et al., General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids, Proc. Natl. Acad. Sci. USA, 82: 5132 (1985). |
| Hu et al., B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells, J. Immunol., 182: 1421-8 (2009). |
| Hu et al., Noncanonical NF-B regulates inducible costimulator (ICOS) ligand expression and T follicular helper cell development, Proc. Nat. Acad. Sci. USA, 108(31):12827-32 (2011). |
| Huang, Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis, Pharmacol. Therapeut., 86: 201-15 (2000). |
| Hutloff et al., ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28, Nature, 397: 263-6 (1999). |
| Ishikawa et al., Prediction of the coding sequences of unidentified human gene. X. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro, DNA Res., 5: 169-76 (1998). |
| Iwahi et al., Amelioration of collagen-included arthritis by blockade of inducible costimulator-B7 homologous protein costimulation-B7 homologous protein costimulation, J. Immunol., 4332-9 (2002). |
| Jakobovits et al., Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobin heavy-chain joining region block B-cell development and antibody production, Proc. Natl. Acad. Sci. USA, 90: 2551-5 (1993). |
| Jakobovits et al., Germ-like transmission and expression of a human-derived yeast artificial chromosome, Nature, 362: 255-65 (1993). |
| Jones et al., Replacing the complementary-determining regions in a human antibody with those from a mouse, Nature, 321: 522-5 (1986). |
| Kahan, Immunosuppressive therapy, Curr. Opin. Immunol., 4: 553-9 (1992). |
| Kelsey et al., Species-and tissue-specific expression of human alpha 1-antitrypsin in transgenic mice, Genes Devel., 1(2): 161-71 (1987). |
| Khare et al., Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenis mice, Proc. Natl. Acad. Sci. USA., 97(7):3370-5 (2000). |
| Khayyamian et al., ICOS-ligand, expressed on human endothelial cells, costimulates h1 and Th2 cytokine secretion by memory CD4+ T cells. Proc. Natl. Acad. Sci. USA, 99(9): 6198-203 (2002). |
| Kimmel et al., Preparation of cDNA and the generation of cDNA libraries: Overview. Meth. Enzymol., 152: 307-16 (1987). |
| Kitts et al., A method for producing recombinant baculovirus expression vectors at high frequency, Biotechniques, 14: 810-7 (1993). |
| Kohler et al., Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256(5517): 495-7 (1975). |
| Kollias et al., Regulated expression of human a gamma-, beta-, and hybrid gamma beta-globin genes in transgenic mice: manipulation of the developmental expression patterns, Cell, 46(1): 89-94 (1986). |
| Kontermann, Bispecific Antibodies: Developments and Current Perspectives, Bispecific Antibodies, 1-28 (2011). |
| Kostelny et al., Formation of a bispecific antibody by the use of leucine zippers, J. Immunol., 148(5): 1547-53 (1992). |
| Kotzin, Systemic lupus erythematosus, Cell, 85: 303-6 (1996). |
| Kremer et al., Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4lg, New Engl. J. Med., 349(20): 1907-15 (2003). |
| Krumlauf et al., Developmental regulation of alpha-fetoprotein genes in transgenic mice, Mol. Cell. Biol., 5(7): 1639-48 (1985). |
| Langer et al., Biocompatibility of polymeric delivery systems for macromolecules, J. Biomed. Mater. Res. 15: 267-277 (1981). |
| Langer, Controlled release of macromolecules, Chem Tech., 12: 98-105 (1982). |
| LaPlanche et al., Phosphorothioate-modified oligodeoxyribonucleotides. III. NMR and UV spectroscopic studies of the Rp-Rp, Sp-Sp, and Rp-Sp duplexes, [d(GGSAATTCC)]2, derived from diastereomeric 0-ethyl phosphorothioates, Nucl. Acids Res., 14(22): 9081-93 (1986). |
| Leder et al., Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development, Cell, 45(4): 485-95 (1986). |
| Lederman et al., A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4, Molec. Immunol., 28: 1171-81 (1991). |
| Lesk, Computational molecular biology, Oxford University Press, N.Y. (1996) [Table of Contents]. |
| Li et al., Beta-endorphin omission analogs: Dissociation of immunoreactivity from other biological activities, Proc. Natl. Acad. Sci. USA, 77: 3211-4 (1980). |
| Ling et al., Cutting edge: Identification of GL50, a novel B7-line protein that functionally binds to ICOS receptor, J. Immunol., 164(4): 1653-7 (2000). |
| Lonberg et al., Antigen-specific human antibodies from mice comprising four distinct genetic modifications, Nature, 368(6474): 856-9 (1994). |
| Lonberg et al., Human antibodies from transgenic mice, Intern. Rev. Immunol., 13(1): 65-93 (1995). |
| Lonberg, Transgenic approaches to human monoclonal antibodies, Handbook of Experimental Pharmacology, 113: 49-101 (1994). |
| Lowman et al., Bacteriophage Display and Discovery of Peptide Leads for Drug Development, Ann. Rev. Biophys. Biomol. Struct. 26:401-24 (1997). |
| Lucklow, Baculovirus systems for the expression of human gene products, Curr. Opin. Biotech., 4: 564-72 (1993). |
| Luckow et al., Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia coli, J. Virol., 67: 4566-79 (1993). |
| Lutz et al., ICOS/B7RP-1 Interference in mouse kidney transplantation, Transplantation, 84(2): 223-30 (2007). |
| MacCallum et al., Antibody-antigen Interactions: Contact analysis and finding site topography, J. Mol. Biol., 262(5): 732-45 (1996). |
| MacDonald, Expression of the pancreatic elastase I gene in transgenic mice, Hepatology, 7(1 Suppl): 42S-51S (1987). |
| Magnan et al., Relationship between natural T cells, atopy, IgE levels, and IL-4 production, Allergy, 55: 286-90 (2000). |
| Marks et al., By-passing immunization human antibodies from V-gene libraries displayed on phage, J. Molec. Biol., 222: 581 (1991). |
| Marsters et al., Interaction of the TNF Homologues BlyS and APRIL with the TNF Receptor Homologues BCMA and TACI, Curr. Biol. 10:785-8 (2000). |
| Marston et al., Solubilization of protein aggregates, Meth. Enzymol. 182: 264-75 (1990). |
| Mason et al., The hypogonadal mouse: Reproductive functions restored by gene therapy, Science, 234: 1372-78 (1986). |
| McAdam et al., Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J. Immunol. 165(9): 5035-40 (2000). |
| McDonald et al., Isolation of RNA using guanidinium salts, Meth. Enzymol., 152: 219 (1987). |
| Medesan et al., Comparative studies of rat IgG to further delineate the Fc:FcRn interaction site, Eur. J. Immunol., 28(7): 2092-100 (1998). |
| Mendez et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, Nat. Genet., 15(2): 146-56 (1997). |
| Merrifield et al., Solid phase peptide synthesis. I. The synthesis of a tetrapeptide, J. Amer. Chem. Soc. 85: 2149 (1963). |
| Metzler, et al., Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CE28, Nat. Struct. Biol., 4: 527-531 (1997). |
| Milgrom et al., Treatment of allergic asthma with monoclonal anti-IgE antibody, New Engl. J. Med., 341(26): 1966-73 (1999). |
| Mogram et al., Developmental regulation of a cloned adult beta-globin gene in transgenic mice, Nature, 315(6017): 338-40 (1985). |
| Morrison, et al, Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad. Sci. USA, 81: 6851-5 (1985). |
| Mukhopadhyay et al., Identification and Characterization of a Novel Cytokine, THANK, a TNF Homologue That Activates Apoptosis, Nuclear Factor-KB, and c-June NH2Terminal Kinase, J. Biol. Chem., 274(23):15978-81 (1999). |
| Muyldermans et al., Single domain camel antibodies: current status. J. Biotechnol. 74: 277-302 (2001). |
| Needlemen, et al, A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins, J. Mol. Biol., 48: 443-53 (1970). |
| Neuberger et al., Generating high-avidity human Mabs in mice. Nat. Biotechnol. 14: 826 (1996). |
| Ngo et al., The protein folding problem and tertiary structure prediction, Merz et al, (Ed.), Birkhauser, Boston, MA, 433 and 492-495 (1994). |
| Ogden, et al, Electrophoresis in agarose and acrylamide gels, Meth. Enzymol. 152: 61 (1987). |
| Oren et al. Structural Basis of BlyS Receptor Recognition, Nature Structural Biology 9(4): 288-92 (2002). |
| Ornitz et al., Elastase I promoter directs expression of human growth hormone and SV40 T antigen genes to pancreatic acinar cells in transgenic mice, Cold Spring Harbor Symp. Quant Biol. 50: 399-409 (1986). |
| Pinkert et al., An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice, Genes Devel., 1(3): 268-76 (1987). |
| Rahman et al., Systemic lupus erythematosus, N. Engl. J. Med., 358:929-39 (2008). |
| Ravetch et al., IgG Fc receptors, Annu. Rev. Immunol., 19: 275-90 (2001). |
| Readhead et al., Expression of a myelin basic protein gene in transgenic shiverer mice: Correction of the dysmyelinating phenotype, Cell, 48(4): 703-12 (1987). |
| Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company (1990) [Table of Contents]. |
| Rentero et al., Screening of large molecule diversities by phage display, Chimia, 65: 843-5. (2011). |
| Richter et al., Tumor necrosis factor-alpha regulates the expression of inducible costimulator receptor ligand on CD34+ progenitor cells during differentiation into antigen presenting cells, J. Biol. Chem., 276(49): 45686-93 (2001). |
| Riechmann, et al, Reshaping human antibodies for therapy, Nature, 332: 323-327 (1988). |
| Riley et al., the CD28 family: a T-cell rheostat for therapeutic control of T-cell activation, Blood, 105: 13-21 (2005). |
| Roberts et al., RNA-Peptide Fusions for the in vitro Selection of Peptides and Proteins, Proc. Natl. Acad. Sci. USA, 94: 12297-302 (1997). |
| Rudikoff et al., Single amino acid substitution altering antigen-binding specificity, Proc. Natl. Acad. Sci. USA, 79: 1979-83 (1982). |
| Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) [Table of Contents]. |
| Samoylova et al. Phage probes for malignant glial cells, Mol. Cancer Ther., 2:1129-1137 (2003). |
| Sani, Tissue-specific expression of rat myosin light-chain 2 gene in transgenic mice, Nature, 314: 283-86 (1985). |
| Schultz et al., B7-mediated costimulation and the immune response, Blood Rev., 10(2): 111-27 (1996). |
| Scott et al., Searching for Peptide Ligands with an Epitope Library, Science, 249: 386-390 (1990). |
| Sekut et al., Characterization of a Human Monoclonal Antibody that Antagonizes B-Lymphocyte Stimulator Bioactivies, abstract (2002). |
| Sequence alignment, 1 page, Ling et al. U.S. Pat. No. 6,521,749. |
| Shields et al., High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RI I, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R, J. Biol. Chem., 276(9): 6591-604 (2001). |
| Shimamoto et al., Peptibodies: A flexible alternative format to antibodies. MAbs, 4(5): 586-91 (2012). |
| Shu et al., B cell maturation protein is a receptor for the tumor necrosis factor family member Tall-1, Proc. Natl. Acad. Sci. USA, 97(16):9156-61. (2000). |
| Shu et al., TALL-1 is a Novel Member of the TNF Family that is Down-Regulated by Mitogens, J. Leukocyte Biol. 65:680-3 (1999). |
| Sidman et al., Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid, Biopolymers, 22: 547-56 (1983). |
| Sifuentes et al., New targets in Systemic Lupus (part 2/2), Reumatologia Clinica (English Edition), 8(5):263-9 (2012). |
| Skolnick et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era, Trends in Biotech, 18(1): 34-9 (2000). |
| Smith et al., Biocomputing: Informatics and genome projects, Academic Press, N.Y. (1993) [Table of Contents]. |
| Smith et al., The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death, Cell, 76:959-62 (1994). |
| Songsivilai et al., Bispecific antibody: A tool for diagnosis and treatment of disease, Clin. Exp Immunol., 79(3): 315-21 (1990). |
| Stec et al., Automated solid phase synthesis, separation and stereochemistry of phosphothioate analogues of oligodeoxyribonucleotides, J. Am. Chem. Soc., 106: 6077 (1984). |
| Stein et al., Physicochemical properties of phosphorothioate oligodeoxynucleotides, Nucl. Acids Res., 16(8): 3209-21 (1988). |
| Stoll et al., Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus, Ann. Rheum Dis., 55:756-60 (1996). |
| Streltsov et al., Structure of a shark IgNAR antibody variable domain and modeling of an early-developmental isotype. Protein Sci. 14: 2901-9 (2005). |
| Swift et al., Tissue-specific expression of the rat pancreatic elastase I gene in transgenic mice, Cell, 38(3): 639-46 (1984). |
| Tafuri et al., ICOS is essential for effective T-helper-cell response, Nature, 409:105-9 (2001). |
| Takasaki et al., Structure-based Design and Characterization of Exocyclic Peptidomimetics that Inhibit TNFa Binding to its Receptor, Nat. Biotech., 15:1266-1270 (1997). |
| Tan et al., Local Production of B Lymphocyte Stimulator (BlySTM) Protein in Human Arthritic Joints, abstract. (2002). |
| Taylor et al., A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins, Nucl. Acids Res., 20(23): 6287-95 (1992). |
| Taylor et al., Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM, Int. Immunol., 6(4): 579-91 (1994). |
| Telleman et al., The role of the Brambell receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile, Immunology, 100(2): 245-51 (2000). |
| Thompson et al., BAFF Binds to the Tumor Necrosis Factor Receptor-Like Molecule B Cell Maturation Antigen and is Important for Maintaining the Peripheral B Cell Population, J. Exp. Med., 192:129-35 (2000). |
| Thomsen et al., Promoter-regulatory region of the major immediate early gene of human cytomegalovirus, Proc. Natl. Acad. Sci. USA, 81(3): 659-63 (1984). |
| Thornton et al., Protein structure: Prediction of progress at last, Nature, 354(6349): 105-6 (1991). |
| Totsuka et al., Amerliorating effect of anti-inducible costimulator monoclonal antibody in a murine model of chronic colitis, Gastroenterology, 410-21 (2003). |
| Tuaillon et al., Biased utilization of DHQ52 and JH4 gene segments in a human Ig transgenic minilocus independent of antigenic selection, J. Immunol., 152(6): 2912-20 (1994). |
| U.S. Appl. No. 12/286,099, Final Office Action dated Oct. 13, 2011. |
| U.S. Appl. No. 12/286,099, Non-final Office Action dated Jan. 28, 2011. |
| U.S. Appl. No. 12/286,099, Restriction Requirement Office Action dated Jul. 6, 2010. |
| U.S. Appl. No. 11/359,254, now U.S. Pat. No. 7,708,993—Final Office Action dated Jul. 16, 2008. |
| U.S. Appl. No. 11/359,254, now U.S. Pat. No. 7,708,993—Nonfinal Office Action dated Feb. 23, 2007. |
| U.S. Appl. No. 11/359,254, now U.S. Pat. No. 7,708,993'Nonfinal Office Action dated May 22, 2009. |
| United States Patent and Trademark Office, International Search Report for PCT/US02/15273 dated Apr. 22, 2003. |
| Vajdos et al., Comprehensive functional maps of the Antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis, J. Mol. Biol., 320(2): 415-28 (2002). |
| Verhoeyen et al., Reshaping human antibodies: Grafting an antilysozyme activity, Science, 239: 1534-8 (1988). |
| Villa-Kamaroff et al., A bacterial clone synthesizing proinsulin, Proc. Natl. Acad. Sci U.S.A., 75: 3727-31 (1978). |
| Voet et al., Biochemistry, John Wiley & Sons, 1: 126-8 and 230 (1990). |
| von Heinje, Sequence Analysis in Molecular Biology, Academic Press (1987) [Table of Contents]. |
| Vratsanos et al., ‘Systemic Lupus Erythematosus’, Samter's Immunological Diseases, Ch. 39, 6 Ed. (2001). |
| Wagner et al.: Nucleotide sequence of the thymidine kinase gene of herpes simplex virus type 1, Proc. Natl. Acad. Sci. U.S.A., 78: 1441-5 (1981). |
| Wahl et al., Interaction of B&RP1 with ICOS negatively regulates antigen presentation by B cells, Inflammation, 27(4): 191-200 (2003). |
| Wahl et al., Molecular hybridization of immobilized nucleic acids: theoretical concepts and practical considerations. Methods Enzymol., 152: 399-407 (1987). |
| Wahl et al., Renal tubular epithelial expression of the costimulatory molecule B7RP-1 (Inducible Costimulator Ligand), J. Am. Soc. Nephrol., 13: 1517-26 (2002). |
| Walter et al., New targets in systemic Lupus (Part 2/2). Reumatologia Clinica, 8(5): 263-9 (2012). |
| Wang et al., Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS, Blood, 96(8): 2808-13 (2000). |
| Ware, APRIL and BAFF Connect Autoimmunity and Cancer, J. Exp. Med., 192(11): F35-F37 (2000). |
| Ware, Decoy Receptors Thwart B Cells, Nature, 404:949-950 (2000). |
| Watanabe et al., Down-regulation of ICOS Ligand by Interaction with ICOS functions as a regulatory Mechanism for Immune Responses, J. Immunol., 180(8):5222-34 (2008). |
| Wells et al., Rapid Evolution of Peptide and Protein Binding Properties in Vitro, Curr. Opin. Biotechnol, 3:355-62 (1992). |
| Wu et al., Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues, J. Mol. Biol., 294: 151-62 (1999). |
| Xia et al., TACI is a TRAF-Interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation, J. Exp. Med., 192:137-43 (2000). |
| Yamamoto et al., Identification of a functional promoter in the long terminal repeat of Rous sarcoma virus, Cell, 22(3): 787-97 (1980). |
| Yoshinaga et al., T-cell co-stimulation through B7RP-1 and ICOS, Nature. 402(6763): 827-32 (1999). |
| Yoshinga et al., Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS, Int. Immun., 12(10): 1439-47 (2000). |
| Yu et al., ARPIL and TALL-1 and Receptors BCMA and TACI: System for Regulating Humoral Immunity, Nat. Immunol. 1:252-256 (2000). |
| Zhang et al., Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus. J. Immunology, 166:6-10 (2001). |
| Zhang et al., ICOS-dependent and -independent functions of memory CD4 T cells in allograft rejection, Am. J. Transplant., 8: 497-506 (2008). |
| Zola, Using monoclonal antibodies: Soluble antigens. Monoclonal Antibodies: A Manual of Techniques, CRC Press, pp. 147-158 (1987). |
| Zon et al., Phosphorothioate oligonucleotides: Chemistry, purification, analysis, scale-up and future directions, Anti-Cancer Drug Design, 6(6): 539-68 (1991). |
| Zou et al., Gene targeting in the lgx locus: Efficient generation of I chain-expressing B cells, independent of gene rearrangements in lgx, EMBO J., 12: 811-20 (1993). |
| Singh et al., “The T cell in Sjogren's syndrome: Force majeure, not spectateur,” Journal of Autoimmunity 39:229-233 (2012). |
| Number | Date | Country | |
|---|---|---|---|
| 20170066845 A1 | Mar 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61780260 | Mar 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14203123 | Mar 2014 | US |
| Child | 15258750 | US |
